Introduction
============

Cholangiocarcinoma (CCA) is a malignancy originating from the epithelial cells of biliary tree. It is classified into intrahepatic cholangiocarcinoma (ICC), hilar and distal cholangiocarcinoma according to anatomical location[@B1]. Both hilar and distal cholangiocarcinoma are known as extrahepatic cholangiocarcinoma (ECC). CCA accounts for about 3% of all alimentary malignancies and is the second most common hepatobiliary malignancy just following hepatocellular carcinoma (HCC). The incidence of CCA is relatively higher in Asian countries compared to western countries. The highest annual morbidity of CCA is in southeast Asia, ranging from 0.1/100,000 to 85/100,000. In contrast, in Europe the morbidity ranges from 0.45/100,000 to 3.36/100,000[@B2]. Recently, the incidence of CCA tends to show a worldwide rise, especially ICC[@B3]-[@B6]. In US, ICC age-adjusted incidence rate increased from 1.42 to 1.82/100,000 in males and from 0.98 to 1.45 in females between 1999 and 2013[@B8]. Notably, the increasing ICC incidence is thought to be influenced by the criteria modification of CCA classification in the International Classification of Diseases for Oncology (ICD-O) coding system [@B3], [@B9].

Many factors contribute to CCA tumorigenesis. Cholestasis and inflammation are key pathological factors in CCA[@B10]. Some oncogenes such as TP53, KRAS, FGFR2, IDH1, IDH2 are proved to be associated with CCA[@B11]. ECC usually leads to bile duct obstructive symptoms including painless jaundice and acute cholangitis while ICC develops as intrahepatic mass with non-specific symptoms such as abdominal pain or cachexy[@B12], [@B13]. Lacking of apparent and specific symptoms and sensitive diagnostic markers, most CCA patients are diagnosed at late stage. Currently, surgical removal is the preferred treatment choice for CCA. However, the prognosis keeps very poor with the overall 5-year-survival rate around 10%[@B14].

RNAs with no protein-coding-function are collectively named non-coding RNA (ncRNA). NcRNA can be classified into microRNA (miRNA), long-noncoding RNA (lncRNA) and circular RNA (circRNA). MiRNA, a ncRNA subtype of 20\~22nt, is involved in CCA progress and can be used as circulating prognostic biomarker[@B15]. LncRNA is ncRNA longer than 200nt in length and lncRNA contributes to a major part of human RNA, according to a transcriptome analysis[@B16]. However, lncRNA used to be thought as the noise of transcription for many years. Until recently, the function of lncRNA has been reported in multiple pathophysiological conditions. 166 diseases are analyzed to be involved of lncRNA dysfunction, including cancer, neurodegeneration disease and cardiovascular disease[@B17]. LncRNA has been proved to be associated with the development of different tumor types, including HCC, CCA, prostate cancer and so on[@B18]. Studies indicate that lncRNA can regulate gene expression in cancer by three levels: the genomic sequence of locus, the act of transcription and the RNA product itself[@B19], [@B20]. LncRNA may function by affecting gene transcription, targeting RNA polymerase II, regulating splicing, taking part in epigenetic regulation and interacting with RNA molecules[@B17]. For example, lncRNA may help forming higher order chromatin structures, such as intra- and inter-chromosomal loops and nuclear compartmentalization. LncRNA transcription can influence functional gene expression [@B19], [@B21]. It also can regulate gene expression by interacting with DNA fragment directly, chromatin complexes, DNA/RNA-binding proteins (DBP/RBPs) or modulators of proteins and enzyme cofactors. LncRNA can compete with miRNA as compete endogenous RNA (ceRNA), which contributes to multiple biological processes and tumorigenesis [@B22]-[@B24]. There are lots of studies on lncRNA in various cancers, as well as in CCA. In this review, we would summarize lncRNA\'s involvement in CCA development and possible mechanisms.

LncRNA in CCA development
=========================

LncRNA is abnormally expressed in CCA tissues
---------------------------------------------

Studies from different groups give a whole landscape of upregulated or downregulated lncRNAs in CCA. 1434 lncRNAs were observed to be specifically expressed in bile duct cancer tissues, in which 929 upregulated and 505 down-regulated[@B25]. Lv, L. and his colleagues reported that 2148 lncRNAs were upregulated while 568 lncRNAs were downregulated in ICC tissues compared with normal tissues[@B26]. Jianguo Wang\'s report showed a similar result with 2773 lncRNAs upregulated and 2392 lncRNAs downregulated in ICC tissues [@B27]. Another study by Zhang, F., et al. identified that 268 lncRNAs were differentially expressed in ECC(78 lncRNAs upregulated, 190 lncRNAs downregulated) [@B28].

The relationship of some differentially expressed lncRNAs (especially upregulated lncRNAs) with CCA clinicopathological characteristics were also reported. The upregulated lncRNAs are associated with tumor size, tumor stage, lymph node metastasis or postoperative recurrence, *etc*. For instance, upregulated lncRNA Sox2ot is related with lymph node invasion (*P*=0.0308), TNM stage (*P*=0.0072) and postoperative recurrence (*P*=0.0019) [@B29]. Besides, both lncRNA UCA1(urothelial carcinoma associated 1) and CCAT1 involve in CCA clinicopathological conditions [@B30]-[@B32]. Interestingly, the upregulation of lncRNA CPS1-IT1 is associated with poorer liver function[@B33]. To give a better piece of knowledge, we summarized the upregulated lncRNAs and their correlation with CCA clinicopathologic characteristics in Table [1](#T1){ref-type="table"}.

LncRNA promotes CCA proliferation, migration and invasion
---------------------------------------------------------

The deregulated expression of lncRNAs may be related with CCA development and progression. These lncRNAs may promote proliferation, migration and invasion of CCA cells including lncRNA AFAP1- AS1, ASAP1-IT1, CCAT1, CCAT2, H19, HULC, LINC01296, ENST0000058480.1, ENST00000517758.1, MALAT1, NEAT1, PANDAR, SNHG1, Sox2ot, SPRY4-IT1, TP73-AS1 *etc.* [@B23], [@B29], [@B30], [@B34]-[@B49]. In ICC, LncRNA CPS1-IT1 and TLINC are highly expressed [@B33], [@B50]. LncRNA CPS1-IT1 promotes cancer cell proliferation, metastasis and inhibits apoptosis[@B33]. LncRNA TLINC increases cancer cell migration[@B50]. In ECC, LncRNA PCAT1 is upregulated, promoting cancer cell proliferation, metastasis and inhibiting apoptosis[@B51]. The upregulated lncRNAs in CCA and their functions in cancer progression were also summarized in Table [1](#T1){ref-type="table"}.

LncRNA promotes EMT in CCA development
--------------------------------------

Epithelial-mesenchymal transition (EMT) is a biological process, regulating the conversion of cells from epithelial to mesenchymal state. Mesenchymal cells are lack of intercellular junctions and can move throughout the extracellular matrix, in contrast, epithelial cells are less migratory[@B52]. EMT are associated with embryonic development after fertilization, tissue regeneration, cancer progression and metastasis respectively. Primary tumor epithelial cells convert into invasive and metastatic mesenchymal tumor cells with enhanced mobility via the third type EMT process[@B52], [@B53]. It is suggested that lncRNA is involved in CCA tumorigenesis by inducing EMT[@B31], [@B37], [@B39], [@B54]. In this process, it accompanies with N- cadherin and Vimentin enhancement and E-cadherin downregulation [@B53]. In contrast, silencing EMT- related-lncRNA reverses the process. For instance, Xia, X. L. et al. silenced a colorectal-cancer-related lncRNA CRNDE and observed E-cadherin was significantly increased, while N-cadherin and Vimentin were lost in ICC cell lines [@B54]. LncRNA UCA1 also can promote EMT formation[@B32]. When silencing UCA1, Vimentin and N-cadherin were decreased with enhanced expression of E-cadherin. LncRNA CCAT1 is involved in EMT process in ICC as well. Knockdown of CCAT1 upregulates E-cadherin and downregulates N-cadherin and Vimentin[@B31]. LncRNA NEAT1 promotes cholangiocarcinoma metastasis through suppressing expression of E-cadherin partly by binding EZH2[@B44]. There are other lncRNAs which are also reported to induce EMT processes in CCA development (see Table [1](#T1){ref-type="table"}). All these studies demonstrate that it may be a common and crucial phenomenon for lncRNA in CCA development via activating EMT. However, the exact mechanisms of lncRNA promoting the EMT need further studies.

LncRNA activates oncogenic signaling pathways in CCA development
----------------------------------------------------------------

Cancer-related signaling pathways can be influenced by abnormally expressed lncRNA and may be the reasonable mechanism of CCA development. The phosphatidylinositol 3-kinase(PI3K)/AKT pathway is a key driver in carcinogenesis, modulating cell survival, differentiation, angiogenesis, and cellular migration[@B55]. LncRNA UCA1 promotes CCA progression by activating AKT/GSK-3β/CCND1 signaling pathway [@B32]. Knockdown of UCA1 in CCA cell lines, phosphorylated-AKT and phosphorylated- GSK-3β decreased, which further inhibiting the expression of CCND1.

The canonical Wnt/β-catenin pathway is an ancient and evolutionarily conserved signaling pathway that is critical for embryo development and adult tissue homeostasis[@B56], [@B57]. Wnt pathway is highly activated in CCA with macrophages activation. Inhibition of Wnt signaling in animal models can markedly reduce cancer cell proliferation and increase apoptosis, resulting in tumor regression[@B58]. LncRNA PCAT1 is reported to activate Wnt/β-catenin signaling and promote ECC progression[@B51]. Recent studies further demonstrate that lncRNA may participate in the pathogenesis of CCA in a Wnt pathway dependent manner[@B51], [@B59]. For example, transcribed-ultraconserved regions (T-UCRs, a group of lncRNAs that harbor ultraconserved fragments) were proved to be the downstream mediators of the Wnt/β-catenin pathway, which was upregulated considerately in human CCA tissues[@B59]. After treating with Wnt inhibitors ICG-001 and C-59 in rat CCA models, uc.158- (an intergenic 224nt T-UCR located at chromosome 5) was reduced and cancer cell growth was depressed[@B59]. Collectively, lncRNA contributes to CCA tumorigenesis and development by regulating crucial oncogenic signaling pathways.

LncRNA influences cellular metabolism in CCA development
--------------------------------------------------------

LncRNA may affect pathophysiological metabolism of CCA[@B60]. It is well known that abnormal glutamine is characteristic in tumor tissues and related to tumorigenesis and development[@B61]. LncRNA taurine upregulated gene 1 (TUG1), a highly expressed lncRNA in ICC, is demonstrated to promote abnormal glutamine metabolism via TUG1/miR-145/Sirt3/GDH regulatory network (see Figure [1](#F1){ref-type="fig"}) [@B24]. The high expression of lncRNA TUG1 is negatively correlated with the expression of miR-145. Co-transfection and rescue studies showed that TUG1 could increase glutamine consumption, α-KG production and ATP levels by counteracting with miR-145. Besides, lncRNA TUG1/miR-145 were able to regulate Sirt3 and GDH expression, which were involved in glutamine metabolism in ICC cells. Therefore, a reasonable explanation is that lncRNA TUG1 promotes CCA proliferation, invasion and migration by affecting glutamine metabolism. It is unclear whether lncRNA also regulates other metabolic processes in CCA development.

The possible acting mechanisms of lncRNA in CCA
===============================================

LncRNA regulates nearby or host genes transcription
---------------------------------------------------

LncRNA may modulate the transcription and expression of nearby mRNA genes[@B62]. In CCA, the co-expression status of host gene and lncRNA was also studied. CPS1 protein, coded by CPS1 gene, is a crucial enzyme of urea cycle. CPS1 deficiency may lead to central nervous system disorders. The co-expression of CPS1 gene and its lncRNA CPS1 intronic transcript 1 (CPS1‑IT1) was analyzed[@B33]. CPS1 and CPS1-IT1 were co-upregulated in ICC tissues with CPS1 protein enhanced, which was negatively associated with ICC prognosis. Moreover, CPS1 was depressed by silencing CPS1-IT1, resulting in reduced cell proliferation and enhanced apoptosis. However, the exact regulatory mechanism between CPS1-IT1 and CPS1 in ICC keeps unclear.

Actin filament associated protein 1 antisense RNA 1 (lncRNA AFAP1-AS1) is a type of lncRNA transcribed from the antisense strand of AFAP1 gene locus. The second AFAP1-AS1 exon overlaps with AFAP1 exons 14, 15 and 16. AFAP1-AS1 is involved in multiple human cancers including pancreatic and biliary carcinoma[@B63], [@B64]. Knockdown AFAP1-AS1 in CCA cells resulted in elevated expression of AFAP1 mRNA and protein, leading to loss of stress filament integrity. Therefore, AFAP1-AS1 may promote CCA growth, proliferation, and invasion by interfering with AFAP1 expression[@B35].

LncRNA binds EZH2 and mediates epigenetic gene silencing
--------------------------------------------------------

PRC2 (polycomb repressive complex 2) possesses histone methyltransferase activity and trimethylates histone H3 on lysine 27 (the complex is called H3K27me3), one of transcriptionally silent chromatin markers. Enhancer of zeste homolog 2 (EZH2) is the functional enzymatic component of this complex[@B65]. Some lncRNAs are reported to directly bind with EZH2 and regulate a spectrum of gene transcription. One study is about the lncRNA SNHG1-EZH2-CDKN1A regulatory network in CCA development. LncRNA SNHG1 is an oncogenic lncRNA in CCA. It directly binds with EZH2, then epigenetically silencing targeting genes by regulating H3K27me3[@B47]. The main target in this process is CDKN1A. CDKN1A is proved to be negatively involved in CCA tumorigenesis. Silencing SNHG1 leads to high expression of CDKN1A with lower tumor proliferation and higher apoptosis in CCA cell lines. LncRNA SPRY4-IT1 can interact with EZH2, lysine specific demethylase 1 (LSD1) and DNA methyltransferase 1 (DNMT1), serving as a scaffold. The complex suppresses the expression of target genes such as KLF2, LATS2, and further promotes CCA development[@B48]. Interestingly, SPRY4-IT1 can also positively modulate the expression of EZH2 through sponging miR-101-3p. Moreover, lncRNA PVT1 also can combine with EZH2 to influence the histone methylation of ANGPTL4 promoter, a possible tumor suppressor gene[@B66]. These findings suggest lncRNA can mediate gene silencing by directly interacting with EZH2 and regulating H3K27me3 in CCA development.

LncRNA sponges miRNA as ceRNA
-----------------------------

LncRNA can sponge miRNA directly by miRNA-response elements and regulate miRNA\'s activity as ceRNA, which is an important lncRNA action mode in CCA[@B25], [@B67]. In a study to characterize interactions between survival-related ceRNAs and CCA, seven major ceRNA clusters were identified. Among them, Cluster 23 and 32 were analyzed to be closely related to CCA patients survival by mediating ceRNA regulation of lncRNA[@B68]. Some lncRNAs have been identified to have specific-binding miRNAs in CCA. Two lncRNAs, H19 and HULC, are upregulated by short-term oxidative stress in CCA cell lines[@B23]. They promote cell migration and invasion in CCA by activating IL-6 and CXCR4 through sponging let-7a/let-7b and miR-372/miR-373 respectively. There are some other studies of lncRNA as ceRNA in CCA. LINC01296(Long Intergenic Non-protein Coding RNA 1296) contributes to CCA development by sponging miR-5095, further regulating the expression of MYCN proto-oncogene bHLH transcription factor [@B40]. Oncogenic lncRNA SPRY4-IT1 can enhance the expression of EZH2 by sponging miR-101-3p in CCA[@B48]. LncRNA PCAT1 (prostate cancer associated transcript 1) is an endogenous competing RNA for miR-122 in ECC, which targets WNT1[@B51]. Then it upregulates the Wnt/β-catenin signaling pathway and promotes ECC progression. Additionally, TUG1/miR-145/Sirt3/GDH regulatory network is also involved in the binding between TUG1 and miRNA-145[@B24]. The identified lncRNAs as ceRNAs in CCA have been summarized in Table [2](#T2){ref-type="table"}.

LncRNA binds functional proteins
--------------------------------

Some lncRNAs are reported to interact with proteins and regulate their localization, activity and functions. For example, lncRNA EPIC1 expression is elevated in CCA. It facilitates CCA progression by directly interacting with MYC protein, then regulating the expression of transcription factor MYC downstream genes [@B69]. The interaction of lncRNA with protein EZH2 has been discussed in Section 2.2.

Clinical applications of lncRNA in CCA
======================================

LncRNA serves as potential diagnostic or prognostic markers
-----------------------------------------------------------

The abnormal upregulated expression of certain lncRNA points to aggressive tumor phenotypes and unfavorable prognosis in CCA. The high expression of lncRNA CCAT1 could be an independent unfavorable prognostic biomarker for CCA[@B30]. LncRNA UCA1 is also an independent prognostic factor for CCA overall survival (*P* = 0.014)[@B32]. The high expression of host gene CPS1 and its associated lncRNA CPS1-IT1 serves as a poor prognostic marker in ICC[@B33]. Upregulation of AFAP1-AS1 is negatively associated with CCA prognosis[@B34], [@B35]. The availability of specimens is an important factor for clinical application. One study demonstrated plasma lncRNA PCAT1, MALAT1, and CPS1-IT1 might serve as potential circulating fingerprints for early diagnosis of hilar cholangiocarcinoma(HCCA)[@B70]. The possible application of lncRNA as diagnostic or prognostic marker is also summarized in Table [1](#T1){ref-type="table"}.

LncRNA may assist chemotherapy in CCA
-------------------------------------

Knocking down or silencing lncRNA in CCA decreases cell proliferation, migration and invasion and promotes cell apoptosis*in vitro.* This indicates that lncRNA can be used as potential novel therapeutic targets for CCA patients. Manipulating of lncRNA expression may also influence the sensitivity of CCA cells to chemotherapy. BAP1(BRCA-1 associated protein-1) is a protein coded by BRCA-1, a tumor suppressor gene in many cancers. It is a member of the ubiquitin C-terminal hydrolase superfamily that plays a critical role in chromatin remodeling [@B45]. Several studies reported late stage ICC was associated with BAP1 loss, suggesting the potential tumor suppressive functions of BAP1 as a chromatin modulator[@B71]-[@B73]. Recently, the negative correlation between BAP1 and lncRNA NEAT1 in CCA is reported [@B45]. Knockdown of BAP1 induces the upregulation of lncRNA NEAT1 in CCA cell lines. The inverse relationship between lncRNA NEAT1 and BAP1 is also supported by the analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Furthermore, BAP1-NEAT1-network can regulate sensitivity to chemotherapy. After depressing BAP1 in CCA cell lines with high NEAT1 expression, it is more sensitive to gemcitabine, TSA, olaparib, b-AP15. Therefore, NEAT1 may be used to assist CCA chemotherapy such as gemcitabine treatment.

Conclusion and Perspective
==========================

Related functional analysis has clearly showed the involvement of lncRNA abnormal expression and CCA development. LncRNA can promote CCA progression, EMT, influence signaling pathway and regulate metabolism. It may function via regulating transcription, chromatin status and interacting with miRNA or proteins. Besides, the application of lncRNA as potential diagnostic or prognostic markers is also proposed. The understanding of lncRNA in CCA tumorigenesis is of great value for early detection and novel therapeutic development. What\'s more, plasma lncRNA as circulating biomarkers may be a meaningful study direction for CCA early diagnosis. More systematic studies are needed to uncover functions and analyze regulatory mechanisms for lncRNA in CCA development.
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![**TUG1/miR-145/Sirt3/GDH regulatory network. (a)** TUG1 can bind to miR-145 directly and inhibit its activity. **(b)** Sirt3, a positive regulator of GDH, is confirmed to be suppressed by miR-145. **(c)** GDH could reverse the inhibitive effect of glutamine metabolism caused by miR-145. **(d)** Knockdown TUG1 in ICC cell would lead to a dramatic decrease of glutamine consumption, indicating a positive glutamine metabolism regulation by TUG1.](jcav10p2407g001){#F1}

###### 

Upregulated lncRNAs in CCA

  LncRNA                                               Cancer         Clinicopathologic Characteristics   Function   Possible Mechanism   Clinical Relevance                             Reference                                                                                                                                                                                                                                                      
  ---------------------------------------------------- -------------- ----------------------------------- ---------- -------------------- ---------------------------------------------- --------------------------- ---- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- --------------------------------------- ----------------
  AFAP1-AS1                                            CCA            √                                   \-         √                    \-                                             √                           \-   1\. Decreasing the expression of c-Myc, Cyclin D1, MMP-2 and MMP-9; 2. Decreasing the AFAP1 expression and promoting cell stress filament integrity   √                               √                                       [@B34], [@B35]
  ASAP1-IT1                                            CCA            √                                   √          \-                   \-                                             √                           √    Interacting with hedgehog signaling pathway                                                                                                           √                               √                                       [@B36]
  CCAT1                                                CCA and ICC    √                                   \-         √                    Associated with histological differentiation   √                           √    Sponging to miR-152 as ceRNA                                                                                                                          Independent prognostic factor   √                                       [@B30], [@B31]
  CCAT2                                                CCA            √                                   √          √                    Linked to tumor size                           √                           √    \-                                                                                                                                                    √                               √                                       [@B37], [@B38]
  CPS1‑IT1                                             ICC            √                                   √          \-                   Associated with poor liver function            √                           √    Co‑expressed with host gene CPS1                                                                                                                      √                               √                                       [@B33]
  EPIC1                                                CCA            \-                                  \-         \-                   \-                                             √                           \-   Directly interacting with Mys                                                                                                                         \-                              \-                                      [@B69]
  H19                                                  CCA            √                                   √          √                    Linked to tumor size                           √                           √    Activing IL-6 by sponging to let-7a/let-7b as ceRNA;                                                                                                  √                               √                                       [@B23], [@B39]
  HULC                                                 CCA            \-                                  \-         \-                   \-                                             √                           \-   Activing CXCR4 by sponging to miR-372/miR-373 as ceRNA                                                                                                \-                              √                                       [@B23]
  HOTAIR                                               CCA            √                                   √          \-                   Linked to tumor size                           √                           √    \-                                                                                                                                                    √                               √                                       [@B74]
  LINC01296                                            CCA            √                                   \-         \-                   \-                                             √                           \-   Modulating MYCN transcription by sponge miR-5095 as ceRNA                                                                                             \-                              √                                       [@B40]
  LncRNAs of ENST00000588480.1 and ENST00000517758.1   CCA            √                                   √          \-                   \-                                             √                           \-   Affecting signaling pathway including p53 signaling pathway                                                                                           √                               √                                       [@B41]
  MALAT1                                               CCA and HCCA   √                                   \-         \-                   Linked to tumor size                           √                           √    1.Activing PI3K/Akt pathway; 2. miR-204-dependent CXCR4 regulation as ceRNA                                                                           √                               √                                       [@B42], [@B43]
  NEAT1                                                CCA            \-                                  \-         \-                   \-                                             √                           √    1.BAP1 protein dependent; 2. Inhibiting E-cadherin expression by EZH2                                                                                 √                               Modulating sensitivity to gemcitabine   [@B44], [@B45]
  PANDAR                                               CCA            √                                   √          \-                   \-                                             √                           √    \-                                                                                                                                                    √                               √                                       [@B46]
  PCAT1                                                ECC            \-                                  \-         \-                   \-                                             √                           \-   Enhancing Wnt/β-catenin signaling through miR-122 repression and WNT1 expression                                                                      \-                              √                                       [@B51]
  PVT1                                                 CCA            \-                                  \-         \-                   \-                                             √                           \-   Binding to epigenetic modification complexes, adjusting the expression of ANGPTL4                                                                     \-                              √                                       [@B66]
  SNHG1                                                CCA            \-                                  \-         \-                   \-                                             √                           \-   Modulating cancer-related gene like CDKN1A by co-operating with chromatin-modifying enzymes as EZH2                                                   √                               √                                       [@B47]
  Sox2ot                                               CCA            √                                   √          \-                   \-                                             √                           \-   \-                                                                                                                                                    Independent prognostic factor   √                                       [@B29]
  SPRY4-IT1                                            CCA            √                                   \-         \-                   \-                                             √                           √    Recruiting EZH2, LSD1 or DNMT1 via sponging to miR-101-3p                                                                                             √                               √                                       [@B48]
  TLINC                                                ICC            \-                                  \-         \-                   \-                                             Increasing cell migration   \-   Infecting cell inflammatory microenvironment induced by TGF-β                                                                                         \-                              \-                                      [@B50]
  TP73-AS1                                             CCA            √                                   \-         \-                   Linked to tumor size                           √                           \-   Suppressing caspase-3 and caspase-9.                                                                                                                  \-                              √                                       [@B49]
  T-UCRs                                               CCA            \-                                  \-         \-                   \-                                             √                           \-   Downstream of Wnt pathway and sponging to miR-193b                                                                                                    √                               √                                       [@B59]
  TUG1                                                 CCA            √                                   √          √                    Linked to tumor size                           √                           √    TUG1/miR-145/Sirt3/GDH regulatory network as ceRNA                                                                                                    √                               √                                       [@B24], [@B75]
  UCA1                                                 CCA            √                                   √          \-                   \-                                             √                           √    1.Facilitating apoptosis via Bcl-2/caspase-3 pathway.2. Activating AKT/GSK-3β/CCND1 axis 3. Upregulating MMP-9                                        √                               √                                       [@B32], [@B76]

^a^ POR: postoperative recurrence; OS: overall survival; TNM stage:T tumor, N node, M metastasis stage; ^b^√ There exists an association of LncRNA; - Unknown

###### 

LncRNAs act as ceRNAs

  LncRNA      Co-regulatory miRNA   Target of miRNA   Function                                                                                       Reference
  ----------- --------------------- ----------------- ---------------------------------------------------------------------------------------------- -----------
  T-UCRs      miR-193b              β-catenin         Downstream mediator of the Wnt/β-catenin pathway and specific for cancer development           [@B59]
  PCAT1       miR-122               WNT1              Promoting Wnt/β-catenin pathway                                                                [@B51]
  H19         let-7a/let-7b         IL-6              Activating pivotal inflammation cytokine IL-6 to regulate cancer cell migration and invasion   [@B23]
  HULC        miR-372/miR-373       CXCR4             Activating Chemokine receptor CXCR4 to regulate cancer cell migration and invasion             [@B23]
  MALAT1      miR-204               CXCR4             Modulating HCCA cell growth, migration and invasion through miR-204-dependent CXCR4            [@B42]
  TUG1        miR-145               Sirt3             TUG1/miR-145/Sirt3/GDH network                                                                 [@B24]
  LINC01296   miR-5095.             MYCN              LINC01296/miR-5095/MYCN network                                                                [@B40]
  SPRY4-IT1   miR-101-3p.           EZH2              Enhancing EZH2 expression                                                                      [@B48]
  CCAT1       miR-152               EMT               Leading to EMT activation of ICC cells                                                         [@B31]
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